IP Verse

Ophthalmological Composition - EP3426226

The patent EP3426226 was granted to Ursapharm Arzneimittel on May 4, 2022. The application was originally filed on Mar 7, 2017 under application number EP17709641A. The patent is currently recorded with a legal status of "Revoked".

EP3426226

URSAPHARM ARZNEIMITTEL
Application Number
EP17709641A
Filing Date
Mar 7, 2017
Status
Revoked
Aug 30, 2024
Grant Date
May 4, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

BITOPFeb 3, 2023HEIDEADMISSIBLE
BAUSCH LOMB IRELANDFeb 2, 2023MAIWALDADMISSIBLE
PHARMA STULLNJun 9, 2022GREINERADMISSIBLE

Patent Citations (15) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONDE102014007423
DESCRIPTIONEP0671161
DESCRIPTIONEP2214658
INTERNATIONAL-SEARCH-REPORTDE102014007423
INTERNATIONAL-SEARCH-REPORTUS2005089500
INTERNATIONAL-SEARCH-REPORTWO03049747
INTERNATIONAL-SEARCH-REPORTWO03053452
OPPOSITIONDE102014007423
OPPOSITIONDE102016203696
OPPOSITIONUS2005043271
OPPOSITIONUS2005089500
OPPOSITIONWO03049747
OPPOSITIONWO03053452
OPPOSITIONWO2015177353
OPPOSITIONWO2017153415

Non-Patent Literature (NPL) Citations (33) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- Anonymous, "ANALYTICAL REPORT Description of test procedure", Pharma Stulln GmbH, (20220201), page 1, XP093027763
OPPOSITION- Anonymous, "bitop AG- Extremolytes for Life, Nature provides the idea, we add the know-how", Bitop, (20150101), pages 1 - 33, XP093026916
OPPOSITION- Anonymous, "Brill Pharma Lanza HYLO-DUAL", Elfarmaceutico, (20150118), pages 1 - 2, Elfarmaceutico, URL: https://www.elfarmaceutico.es/tendencias/esta-pasando/notifarma/bnll-pharma-lanza-hylo-dual_105474_102.html, (20230224), XP093026879
OPPOSITION- Anonymous, "Gebrauchsanweisung Hylo-Protect: Natriumhyaluronat 0,5 mg/ml und Ectoin", Gebrauchsansweisung, UrsaPharm, Industriestraße, D-66129 Saarbrücken, Industriestraße, D-66129 Saarbrücken, pages 1 - 2, Gebrauchsansweisung, URL: https://www.mediherz-shop.de/images/products/mediherz/beipackzettel/09715226_d.pdf, XP002742588
OPPOSITION- Anonymous, "Gebrauchsanweisung - Vividrin" ectoin EDO Augentropfen", bitop AG, (20150101), pages 1 - 2, XP093027752
OPPOSITION- Anonymous, "Gebrauchsanweisung, Vividrin® ectoin® EDO®", Dr. Gerhard Mann chem.-pharm. Fabrik GmbH, (20210101), pages 1 - 2, XP093027761
OPPOSITION- Anonymous, "Hyaluronic acid", Wikipedia, (20150101), pages 1 - 12, XP093027909
OPPOSITION- Anonymous, "HYLO-DUAL", Brillpharma, (20140501), pages 1 - 4, Brillpharma, URL: https://www.brillpharma.com/en/hylo-dual/, (20230224), XP093026874
OPPOSITION- Anonymous, "HYLO-DUAL: Contra los sintomas oculares de la alergia", Elfarmaceutico Hospitales, (20150119), pages 1 - 2, Elfarmaceutico Hospitales, URL: https://webcache.googleusercontent.com/search?g=cache:OlzpYSmlfpwJ:https://www.elfarmaceuticohospitales.es/actualidad-noticas/item/5025-, (20230224), XP093026882
OPPOSITION- Anonymous, "HYLO-DUAL", URSAPHARM, (20140901), pages 1 - 2, XP093027937
OPPOSITION- Anonymous, "Hylo-Vision® HD 15 ml Augentropfen Natriumhyaluronat 0,1 % ", Hylo-Vison® HD eye drops, Gebrauchsanweisung, (20040101), page 1, XP093027899
OPPOSITION- Anonymous, "Rontis present at CPhl 2014", Rontis Pharmaceuticals, (20141007), pages 1 - 3, Rontis Pharmaceuticals, URL: https://www.rontispharmaceuticals.com/rontis-present-at-cphi-2014/, (20230224), XP093026909
OPPOSITION- Anonymous, "VISCOSITY", Deutsche ApothekerZeitung, DAZ Unabhangige pharmazeutische Zeitschrift fUr Wissenschaft und Praxis, (20120913), pages 27 - 28, Deutsche ApothekerZeitung, DAZ Unabhangige pharmazeutische Zeitschrift fUr Wissenschaft und Praxis, URL: hitps://www.deutsche-apotheker-zeitung.de/daz-az/2012/daz-4, (20230224), XP093026861
OPPOSITION- Anonymous, "VISMED Gel, ZUR NACHHALTIGEN BENETZUNG DES AUGES, comprising 0.3 % by weight of sodium hyaluronate", TRB CHEMEDICA, Vismed® Gel eye drops, (20120101), page 1, XP093027904
OPPOSITION- Dumitriu Severian, "POLYMERIC BIOMATERIALS Second Edition, Revised and Expanded edited by", POLYMERIC BIOMATERIALS, (20020101), page 384, XP093027892
OPPOSITION- European Medicines Agency, Committee For Human Medicinal Products (chmp), "Background review for the excipient boric acid", revision of the guideline on ‘Excipients in the label and package leaflet of medicinal products for human use’ (CPMP/463/00 Rev. 1), European Medicines Agency, (20150723), pages 1 - 19, URL: https://www.ema.europa.eu/documents/report/background-review-excipient-boric-acid-context-revision-guideline-excipients-label-package-leaflet_en.pdf, (20190107), XP055538539
OPPOSITION- Gebrauchsinformation, "Xailin "HA, Natriumhyaluronat Augentropfen 0,2% m/V 10ml", Nicox Pharma, (20140101), page 1, XP093027902
OPPOSITION- Hale Mike, "A drop of the viscoelastic stuff for dry eye", Opticien online, (20150305), pages 1 - 4, XP093027929
OPPOSITION- Heiko A Schiffter-Weinle, "Isotonisierung Wie sich Hilfsstoffmengen berechnen lassen", Deutsche Apotheker Zeitung 2015, Nr. 46, (20151112), page 60, Deutsche Apotheker Zeitung 2015, Nr. 46, (20201123), XP055752892
OPPOSITION- KEMPF, "Uptake and synthesis of compatible solutes as microbial stress responses to high-osmolality environments", Arch Microbiol, (19980000), vol. 170, pages 319 - 330, XP002305932
OPPOSITION- Mueller-Lierheim, "Hyaluronic acid eye drops - what you should know about their rheological properties", Current Contactology; Aktkontaktol, (20151201), pages 1 - 3, XP093027907
OPPOSITION- Rah, M.J., "A review of hyaluronan and its ophthalmic applications", OPTOMETRY - JOURNAL OF THE AMERICAN OPTOMETRIC ASSOCIATION, ELSEVIER, NL, NL , (20110101), vol. 82, no. 1, ISSN 1529-1839, pages 38 - 43, XP027556670
OPPOSITION- Vizol S., "Vizol S Allergy - An ideal solution for preventing eye allergy symptoms", Allergy, (20150921), page 1, XP093027932
OPPOSITION- BRIGNOLE, "Efficacy and safety of 0.18% sodium hyaluronate in patients with moderate dry eye syndrome and superficial keratitis", Graefe's Arch Clin Exp Ophthalmol, (20050000), vol. 243, doi:10.1007/s00417-004-1040-6, pages 531 - 538, XP019342793
OPPOSITION- HELD et al., "Compatible solutes: Thermodynamic properties and biological impact of ectoines and prolines", Biophysical Chemistry, (20100000), vol. 152, doi:10.1016/j.bpc.2010.07.003, pages 28 - 39, XP027477809
OPPOSITION- Ruckmani K. et al, "Determination of sodium hyaluronate in pharmaceutical formulations by HPLC-UV", Journal of Pharmaceutical Analysis, (20131001), vol. 3, no. 5, doi:10.1016/j.jpha.2013.02.001, ISSN 2095-1779, pages 324 - 329, XP093027910
OPPOSITION- LAPCIK L., ET AL., "HYALURONAN: PREPARATION, STRUCTURE, PROPERTIES, AND APPLICATIONS.", Chemical Reviews, American Chemical Society, US, US , (19981201), vol. 98., no. 08., doi:10.1021/cr941199z, ISSN 0009-2665, pages 2663 - 2684., XP000789004
OPPOSITION- Labetoulle M. et al, "Osmoprotectants, carboxymethylcellulose and hyaluronic acid multi-ingredient eye drop: a randomised controlled trial in moderate to severe dry eye", EYE, Nature Publishing Group, GB, GB , (20171001), vol. 31, no. 10, doi:10.1038/eye.2017.73, ISSN 0950-222X, pages 1409 - 1416, XP093026781
OPPOSITION- Gomes J A P, "Sodium hyaluronate (hyaluronic acid) promotes migration of human corneal epithelial cells in vitro", BRITISH JOURNAL OF OPHTHALMOLOGY, BMJ Publishing Group, GB, GB , (20040601), vol. 88, no. 6, doi:10.1136/bjo.2003.027573, ISSN 0007-1161, pages 821 - 825, XP093026778
OPPOSITION- ROBERTS, "Organic compatible solutes of halotolerant and halophilic microorganisms", Saline Systems, (20050000), vol. 1, doi:10.1186/1746-1448-1-5, page 5, XP021011381
OPPOSITION- SIMMONS et al., "Efficacy and safety of two new formulations of artificial tears in subjects with dry eye disease: a 3-month, multicenter, active-controlled, randomized trial", Clinical Ophthalmology, (20150415), vol. 2015, no. 9, doi:10.2147/OPTH.S78184, pages 665 - 675, XP055919847
OPPOSITION- Lu Zhi-Yan et al, "High-Throughput Screening for a Moderately Halophilic Phenol-Degrading Strain and Its Salt Tolerance Response", International Journal of Molecular Sciences, vol. 16, no. 12, doi:10.3390/ijms160611834, pages 11834 - 11848, XP093027918
OPPOSITION- Baudouin Christophe et al, "Randomized, phase III study comparing osmoprotective carboxymethylcellulose with sodium hyaluronate in dry eye disease", EUROPEAN JOURNAL OF OPHTHALMOLOGY, Wichtig Publishing, IT, IT , (20120901), vol. 22, no. 5, doi:10.5301/ejo.5000117, ISSN 1120-6721, pages 751 - 761, XP093026773

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents